Lung Cancer Considered

By IASLCScience

Lung Cancer Considered episodes

March 15, 2025 Lung Cancer Considered in Turkish: First-Line Therapies in EGFR Mutant NSCLC
Host: Ece Cali Daylan, Assistant Professor of Medicine, Division of Oncology at Washington University School of Medicine
Guest: Saadettin Kilickap
Guest: Ozden Altundag
57 min
March 14, 2025 Lung Cancer Considered in Hungarian: Lung Cancer Treatment Updates
As part of IASLC's ongoing series of podcasts in world languages, Dr. Balazs Halmos moderates a discussion in Hungarian with Dr. Krisztina Bogos, Dr. Ferenc Rényi-Vámos and Dr. Zsolt Megyesfalvi. The podcast reviews recent advances in lung cancer screening, diagnosis and management with a particular focus on implementation in Hungary. Highlights of the discussion include novel staging and diagnostic tools, state-of-the-art biomarker testing, perioperative therapy and clinical trials access.
Host: Balazs Halmos, MD, Director, Thoracic Oncology & Clinical Cancer Genomics, Montefiore Medical Park at Eastchester, Bronx, New York
Guest: Ferenc Rényi-Vámos, MD, PhD, Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary
Guest: Krisztina Bogos, MD, Thoracic Oncology National Koranyi Institute of Pulmonology, Budapest, Hungary Lung Cancer Research and Pathology
Guest: Zsolt Megyesfalvi, MD, PhD, Semmelweis University and National Institute of Oncology, Budapest, Hungary and National Koranyi Institute of Pulmonology, Budapest, Hungary
1 hr 2 min
March 09, 2025 LCC in Cantonese: WCLC24 Highlights
The 2024 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary.
To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages.
In this episode, host Dr. Sally Lau moderates a discussion in Cantonese Chinese about highlights from the conference with Dr. David Lee and Dr. Molly Li.
26 min
March 05, 2025 Virtual Tumor Board: Stage III ALK+ NSCLC
Virtual Tumor Board: Stage III ALK+ NSCLC by IASLC
49 min
February 28, 2025 Live from TTLC25: Targeted Therapy in Early Stage NSCLC Debate
Live from TTLC25: Targeted Therapy in Early Stage NSCLC Debate by IASLC
26 min
February 24, 2025 The Benefits of Patient Advocacy Groups
In this episode of Lung Cancer Considered, host Dr. Narjust Florez engages in a discussion with patient advocate Summer Farmen. Listen to the episode to learn about Summer’s journey through diagnosis and treatment, and the importance of patient advocate groups.
• Summer Farmen
ALKtALK Program Coordinator
Board Member, ALK Positive, Inc.
31 min
February 20, 2025 Live from TTLC 2025: Mesothelioma and NUT Carcinoma
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of two of the most challenging thoracic malignancies – NUT carcinoma and mesothelioma. Listen to the episode to learn about the role of next-generation sequencing in diagnosis and treatment selection, as well as current and future targeted therapy in the management of both.
Guests
Melina Marmarelis, MD MSCE
Assistant Professor
Medical Director, UPenn Mesothelioma
University of Pennsylvania
Jia Luo, MD
Medical Oncologist, Thoracic Oncology Program, Dana-Farber Cancer Institute
Faculty, Brigham and Women's Hospital and Harvard Medical School
45 min
February 20, 2025 Live from TTLC25: Targeted Therapy in SCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on how small cell lung cancer continues to evolve with new treatment options and recent FDA approval. Listen to the episode to learn about the current standard of care and future therapies with a brief discussion about small cell transformation.
Guest: Triparna Sen, MD
Associate Professor
Director, Lung Cancer PDX Program,
Icahn School of Medicine at Mount Sinai
Guest:
Jacob Sands, MD
Assistant Professor of Medicine, Harvard Medical School
Lowe Cancer Center for Thoracic Oncology
Dana Farber Cancer Institute
30 min
February 14, 2025 LCC in Arabic: Chemo Immunotherapy in Metastatic NSCLC
Descriptions: As part of the IASLC's ongoing series of podcasts in world languages, Dr. Nagla Abdel Karim moderates a discussion in Arabic with Dr. Bashir Abu Aqeel and Dr. Fawzi Abu Rous. The group discusses chemoimmunotherapy in metastatic non-small cell lung cancer.
16 min
February 11, 2025 Virtual Tumor Board: Treating EGFR NSCLC After TKI Resistance
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case involving drug resistance in EGFR mutant NSCLC. This discussion takes the listener through the treatment of EGFR mutant NSCLC after acquired resistance to osimertinib.
Guest: Dr. Yasushi Goto from National Cancer Center, Japan in Tokyo
Guest: Dr. Rachel Sanborn, the Earle A. Chiles Research Institute of the Providence Cancer Institute in Portland, Oregon
46 min

About Lung Cancer Considered

From the publisher's feed

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.